+Vote!
Times Online (Free subscription) | 5 hours ago
The world's second-largest pharmaceuticals group is to abandon its big-is-beautiful model and run its businesses more like small biotech outfits.
+Vote!
The Telegraph (Free subscription) | yesterday
GlaxoSmithKline teams up with Aspen to drive generic drugs
+Vote!
Financial Time (Free subscription) | 2 hours ago
GlaxoSmithKline's shift into generic drugs by means of its partnership with Aspen reflects and develops a trend during recent years by large pharmaceutical companies...
+Vote!
The Pittsburgh Business Times (Free subscription) | yesterday
Competition from generic drugs weighed on GlaxoSmithKline's bottom line in the second quarter, the pharmaceutical company said Wednesday. (GSK)
+Vote!
PR News Wire (Free subscription) | yesterday
LONDON, July 23 /PRNewswire-FirstCall/ -- In a video interview, new CEO
Andrew Witty comments on GSK's second quarter results while also updating
the market on his strategic vision for the business.
The new strategic priorities for GlaxoSmithKline are:
- Grow a diversified global business
- Deliver more products of value
- Simplify GSK's operating model
The interview, podcast and vodcast are...
+Vote!
The Triangle Business Journal (Free subscription) | yesterday
Competition from generic drugs weighed on GlaxoSmithKline's bottom line in the second quarter, the pharmaceutical company said Wednesday. (GSK)
+Vote!
Scotsman.com (Free subscription) | 5 hours ago
GLAXOSMITHKLINE must change to survive the growing threat of generic competition for its leading products, its chief executive warned yesterday.
+Vote!
The Independent (Free subscription) | 5 hours ago
GlaxoSmithKline's new chief executive signalled his intent to launch an expansion drive into the emerging markets yesterday as he revealed his strategic objectives for the first time and announced a "transformational" partnership with a South African drugs company.
+Vote!
The Herald (Free subscription) | 6 hours ago
GlaxoSmithkline, the world’s second-largest drug maker, posted a 3% fall in second-quarter net profit yesterday after strong competition from generic drugs outweighed asset sales and the cost-saving effects of job cuts.
+Vote!
The Telegraph India (Free subscription) | 5 hours ago
Mumbai, July 23: GlaxoSmithKline has entered into an alliance with Onco Therapies Ltd, a joint venture of Strides Arcolab, in branded generics.
+Vote!
Law Blog - WSJ.com (Free subscription) | yesterday
GlaxoSmithKline will make additional changes to its drug-research team and work with a company that sells low-cost medicines in emerging markets. The U.K. drug giant posted weak second-quarter results.
+Vote!
San Fransisco Chronicle (Free subscription) | yesterday
Profits posted Wednesday by Pfizer Inc. and Wyeth show a common theme among pharmaceutical companies _ nearly all the growth they're seeing these days is overseas, driven by emerging markets and the weak dollar. U.K.-based GlaxoSmithKline PLC, which also...
+Vote!
FT.com - Europe homepage (Free subscription) | yesterday
GlaxoSmithKline unveiled a strategic overhaul that includes a plan to sell a wide range of generic medicines under a pioneering deal to boost sales in emerging markets
+Vote!
BBC News (Free subscription) | yesterday
Global drugs giant GlaxoSmithKline wants to broaden its product base as it grapples with tough competition from generic drug makers
+Vote!
Hindu (Free subscription) | yesterday
LONDON: GlaxoSmithKline, the world’s second largest drugmaker, on Wednesday took a bold step into the branded generics marketplace via an alliance with South Africa’s Aspen Pharmacare Holdings. The move, is the latest sign of Glaxo ...